Andere Sprachen Alector, Inc.

Aktien

A2PCBM

US0144421072

ALEC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
5,44 ^USD	-0,91 %		+3,62 %	-31,83 %

14.05.	Transcript : Alector, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:55 AM
08.05.	Alector, Inc. bekräftigt Umsatzprognose für das Jahr bis 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alector to Participate in Upcoming Healthcare Conferences	09.05.
Alector: Q1 Earnings Snapshot	08.05.
Alector : May 2024 Corporate Presentation	08.05.
Alector Reports First Quarter 2024 Financial Results and Provides Business Update	08.05.
Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	08.05.
Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17.04.
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17.04.
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17.04.
Alector, Inc. Announces Board Changes	21.03.
Alector to Participate in Upcoming Healthcare Conferences	28.02.
Alector: Q4 Earnings Snapshot	27.02.
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	27.02.
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27.02.
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27.02.
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call	20.02.
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease	08.02.
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease	08.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alector, Inc.

Aktien

A2PCBM

US0144421072

ALEC

Andere Sprachen

Filter